Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KCNN3 | Q9UGI6 | 2/20 | 0.42 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4846763 | 0.82 | SLC34A1 (0.46) | CRHR1 | |
| SCHEMBL4855605 | 0.79 | MAPT (0.41) | TSHRSMN1; SMN2KCNN3CRHR1MEN1 | |
| SCHEMBL4846780 | 0.76 | CRHR1 (0.40) | CRHR1 | |
| SCHEMBL4857708 | 0.75 | CRHR1 (0.49) | TSHRCRHR1MEN1CYP2C9CYP2C19 | |
| SCHEMBL4852355 | 0.74 | CRHR1 (0.40) | CRHR1 | |
| SCHEMBL31388502 | 0.73 | SMN1; SMN2 (0.59) | TSHRHSD17B10SMN1; SMN2KCNN3MEN1 | |
| SCHEMBL19687281 | 0.71 | HTT (0.57) | TSHRHSD17B10SMN1; SMN2MEN1CYP2C9 | |
| SCHEMBL21143766 | 0.71 | HTT (0.57) | TSHRHSD17B10SMN1; SMN2MEN1CYP2C9 | |
| SCHEMBL4853755 | 0.71 | CRHR1 (0.43) | TSHRCRHR1MEN1CYP2C9CYP2C19 | |
| SCHEMBL4848082 | 0.69 | TP53 (0.49) | TSHRHSD17B10CRHR1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414059-B2 | Pyrazolyl and imidazolyl pyrimidines as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414059-B2 | Pyrazolyl and imidazolyl pyrimidines as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414059-B2 | Pyrazolyl and imidazolyl pyrimidines as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2008-08-19 | — | — | US | disclosed |
| US-20050113382-A1 | Spiro tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | ROCHE PALO ALTO LLC | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113382-A1 | Spiro tetrahydroquinazolines and dihydrocyclopentapyrimidines as CRF antagonists | AVPR2, CRHR1, CRHR2 | TSHR 248/4885HSD17B10 2806/4885SMN1; SMN2 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.